Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.68 |
| ▸ | CDK1 | P06493 | 6/20 | 0.68 |
| ▸ | IKBKB | O14920 | 7/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422645 | 0.93 | CDK1 (0.59) | CDK2CDK1IKBKBCHUKHRH4 | |
| Hydrochloric Acid SCHEMBL5432381 | 0.92 | CDK1 (0.58) | CDK2CDK1IKBKBCHUKHRH4 | |
| SCHEMBL5432126 | 0.86 | CDK2 (0.64) | CDK2CDK1IKBKBCHUKCHEK1 | |
| Hydrochloric Acid SCHEMBL5422005 | 0.85 | CDK2 (0.63) | CDK2CDK1IKBKBCHUKCHEK1 | |
| Hydrochloric Acid SCHEMBL5432132 | 0.85 | CDK1 (0.64) | CDK2CDK1IKBKBHRH4 | |
| SCHEMBL5435591 | 0.85 | CDK2 (0.69) | CDK2CDK1IKBKBCHUKCHEK1 | |
| Hydrochloric Acid SCHEMBL5425696 | 0.84 | CDK2 (0.67) | CDK2CDK1IKBKBCHUKCHEK1 | |
| Hydrochloric Acid SCHEMBL5425667 | 0.83 | CDK2 (0.61) | CDK2CDK1IKBKBCHUKCHEK1 | |
| Hydrochloric Acid SCHEMBL5425584 | 0.83 | CDK2 (0.61) | CDK2CDK1IKBKBCHUKCHEK1 | |
| Hydrochloric Acid SCHEMBL5718664 | 0.81 | CDK2 (0.58) | CDK2CDK1IKBKBCHUKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | claimed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | claimed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | CDK2 26/4885CDK1 477/4885IKBKB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.